HIV
HIV-1 is an RNA retrovirus that infects immune cells through the envelope glycoprotein Env, whose mature gp120/gp41 trimer mediates viral entry into host cells[1]. Mechanistically, gp120 binds CD4 and then the chemokine coreceptors CCR5 or CXCR4, while gp41 refolding brings viral and cellular membranes together for fusion[2][3]. After entry, viral replication depends on reverse transcriptase, protease, and integrase, making these enzymes core targets for antiretroviral research[4][5]. In disease relevance, untreated HIV replication causes progressive CD4+ T-cell loss and immunological abnormalities, increasing infectious and oncological complications[6]. Compared with related forms, HIV-1 remains the main focus because it is described as the most virulent and pathogenic subtype in diagnostic and treatment literature[7]. For experimental applications, entry inhibitors target gp120, gp41, CCR5, or CXCR4, while enzyme inhibitors target reverse transcriptase, protease, or integrase to suppress distinct stages of the HIV life cycle[4][8].
References:
- [1]. Anang S, et al. Characterization of full-length and cytoplasmic tail-truncated envelope glycoproteins incorporated into human immunodeficiency virus (HIV-1) virions and virus-like particles. J Virol. 2025 Dec 23;99(12):e0158525. [Content Brief]
- [2]. Teixeira C, et al. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. Eur J Med Chem. 2011 Apr;46(4):979-92. [Content Brief]
- [3]. Princen K, et al. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev. 2005 Dec;16(6):659-77. [Content Brief]
- [4]. De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. doi: 10.1517/14728214.10.2.241. PMID: 15934866. et al. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. [Content Brief]
- [5]. Palmisano L. Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect Ther. 2007 Feb;5(1):67-75. doi: 10.1586/14787210.5.1.67. PMID: 17266455. et al. Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect Ther. 2007 Feb;5(1):67-75. [Content Brief]
- [6]. Deeks SG, et al. HIV infection. Nat Rev Dis Primers. 2015 Oct 1;1:15035. [Content Brief]
- [7]. Zulfiqar HF, et al. HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health. 2017 Mar 7;5:32. [Content Brief]
- [8]. Greenberg M, et al. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol. 2004 Sep-Oct;14(5):321-37. [Content Brief]
All Product Categories
-
HIV Related Products (903)
Related Products (903)
-
NYAD-13
0 ImagesCat. No.: HY-P10834CAS No.: 1042980-96-0
-
Lefelsiran sodium scrambled negative control
0 ImagesCat. No.: HY-177639BLefelsiran sodium scrambled negative control is the sequence scrambled negative control of Lefelsiran sodium.
-
DIACC-1010
0 ImagesCat. No.: HY-P991428DIACC-1010 is a human monoclonal antibody (mAb) targeting PLA2G1B. DIACC-1010 can be used in HIV infections research.
-
Marsdenoside F
0 ImagesCat. No.: HY-N3318CAS No.: 858360-61-9Marsdenoside F is a polyoxygenated pregnane glycoside isolated from the stems of Marsdenia tenacissima. Marsdenoside F showed no significant cytotoxicity against A549 and MCF-7 cell lines, nor did it exhibit significant anti-HIV activity.
-
HIV-1 inhibitor-20
0 ImagesCat. No.: HY-146753CAS No.: 2758387-58-3
-
NNRT-IN-13
0 ImagesCat. No.: HY-178341NNRT-IN-13 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor that directly inhibiting HIV-1 reverse transcriptase (IC₅₀ = 0.25 μM). NNRT-IN-13 exhibits excellent antiviral activity against wild-type HIV-1 (EC₅₀ = 0.0046 μM) and a broad spectrum of drug-resistant mutants. NNRT-IN-13 exhibits favorable in vivo metabolic and safety profiles. NNRT-IN-13 can be used for human immunodeficiency virus (HIV) research.
-
HIV-1 inhibitor-9
0 ImagesCat. No.: HY-139631CAS No.: 2708201-36-7
-
Zintevir sodium scrambled negative control
0 ImagesCat. No.: HY-177670BZintevir sodium scrambled negative control is the sequence scrambled negative control of Zintevir sodium.
-
Emtricitabine-13C,15N2
0 ImagesCat. No.: HY-17427S2CAS No.: 1217820-69-3Synonyms: BW1592-13C,15N2Emtricitabine-13C,15N2 (BW1592-13C,15N2) is a 13C- and 15N-labeled Emtricitabine (HY-17427). Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.
-
PF-232798
0 ImagesCat. No.: HY-14388CAS No.: 849753-15-7
-
FC-14367
0 ImagesCat. No.: HY-171859CAS No.: 3066893-65-7FC-14367 is a PROTAC degrader targeting the HIV-1 Nef protein. FC-14367 forms a ternary complex between HIV-1 Nef and CRBN, inducing ubiquitination and proteolytic degradation of Nef. FC-14367 restores the expression of CD4 and MHC-I on the cell surface and inhibits Nef-dependent enhancement of HIV-1 replication. FC-14367 can be used in studies related to HIV-1 infection.
-
UK-88947 hydrochloride
0 ImagesCat. No.: HY-129678CAS No.: 137015-76-0UK-88947 hydrochloride is a protease inhibitor with activity in inhibiting the replication of human immunodeficiency virus HIV-1. UK-88947 hydrochloride can be added to cells before infection to block the early steps of HIV-1 replication. The use of UK-88947 hydrochloride shows its specific inhibitory effect on HIV-1. At the same time, when the virus infects cells, it inhibits the action of viral protease and affects the virus replication process.
-
VGD020
0 ImagesCat. No.: HY-182674CAS No.: 1322645-32-8VGD020 is a highly potent and selective Sec61 translocon inhibitor. VGD020 suppresses the expression of cell surface CD4 by inhibiting signal peptide-dependent co-translational ER translocation, interferes with the initiation of ER translocation of dengue virus polyprotein, and reduces the expression of Sortilin in breast cancer cells. VGD020 exhibits broad anti-flavivirus and anti-HIV activities. VGD020 can be used in research related to dengue virus infection, Zika virus infection, yellow fever virus infection, human immunodeficiency virus infection, and breast cancer.
-
NNRT-IN-4
0 ImagesCat. No.: HY-162720NNRT-IN-4 (Compound 10p) is an inhibitor for non-nucleoside reverse transcriptase (NNRT) with an IC50 of 0.713 µM for HIV-1 RT. NNRT-IN-4 exhibits antiviral efficacy, inhibits HIV-1 wildtype and mutant strains with EC50 of 6-63 nM. NNRT-IN-4 exhibits a slight inhibitory activities against hERG (IC50=25.9 µM) and CYP enzymes (IC50>50 µM). NNRT-IN-4 exhibits good tolerability and safety in mice (2 g/kg).
-
TAT-CBD3
0 ImagesCat. No.: HY-P10357CAS No.: 1355359-36-2TAT-CBD3, a 15-amino acid peptide from CRMP2, fused to the TAT cell-penetrating motif of the HIV-1 protein, disrupts CRMP2-NMDAR interaction without change in NMDAR localization.
-
(D-Ala)-Peptide T
0 ImagesCat. No.: HY-106276CAS No.: 106362-33-8(D-Ala)-Peptide T is an octapeptide derived from gp120. (D-Ala)-Peptide T releases chemokines and prevents HIV-1 GP120-induced neuronal death. (D-Ala)-Peptide T can be used in research on infectious and neurological diseases such as AIDS-related dementia.
-
NNRT-IN-17
0 ImagesCat. No.: HY-189211NNRT-IN-17 is a non-nucleoside HIV-1 Reverse Transcriptase inhibitor with an IC50 of 0.095 μM. NNRT-IN-17 exerts its inhibitory effect by binding to the NNRTI binding pocket and adjacent sites, and exhibits antiviral activity against wild-type and multiple NNRTI-resistant mutant strains. NNRT-IN-17 can be used for the study of HIV-1 infection (AIDS).
